HIGHLIGHTS
- who: Toshimitsu Tanaka from the Fudan University, China have published the research: Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab, in the Journal: (JOURNAL)
- what: The authors report changes in the blood bevacizumab concentration of a patient with unresectable colon cancer, in whom FOLFIRI plus bevacizumab treatment was performed safely during hemodialysis.
- how: The results were consistent with those of a study that evaluated the pharmacokinetics of bevacizumab in a patient undergoing dialysis with metastatic CRC and revealed similar Frontiers in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.